Evidence map›Paper›PMID 40830810›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT.

Fei Yao, Heng Lin, Ying-Nan Xue, Yuan-Di Zhuang, Shu-Ying Bian, Ya-Yun Zhang, Yun-Jun Yang, Ke-Hua Pan

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Impact ofDiagnostics (Basel, Switzerland) · 2025
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fei YaoDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Heng LinDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Ying-Nan XueDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Yuan-Di ZhuangDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Shu-Ying BianDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Ya-Yun ZhangDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China.
Yun-Jun YangDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China. yunjunyangyyj@126.com.
Ke-Hua PanDepartment of Radiology, The First Affiliated Hospital of Wenzhou Medical University, No. 1 of Xuefubei Road, Ouhai District, Wenzhou, 325000, Zhejiang Province, China. pankehuapan@126.com.

Funding

Key Laboratory of Novel Nuclide Technologies on Precision Diagnosis and Treatment & Clinical Transformation of Wenzhou City 2023HZSY0012
6 · The paper itself

Abstract

objectiveThis study aimed to construct a multimodal imaging deep learning (DL) model integrating mpMRI and

methodsClinical and imaging data were retrospectively collected from patients with pathologically confirmed prostate cancer (PCa) who underwent radical prostatectomy (RP). Data were collected from a primary institution (Center 1, n = 197) between January 2019 and June 2022 and an external institution (Center 2, n = 36) between July 2021 and November 2022. A multimodal DL model incorporating mpMRI and

resultsFor patients in Center 1, the area under the curve (AUC) for predicting EPE was 0.76 (0.72-0.80), 0.77 (0.70-0.82), and 0.82 (0.78-0.87) for the mpMRI-based DL model, PET/CT-based DL model, and the combined mpMRI + PET/CT multimodal DL model, respectively. In the external test set (Center 2), the AUCs for these models were 0.75 (0.60-0.88), 0.77 (0.72-0.88), and 0.81 (0.63-0.97), respectively. The multimodal DL model demonstrated superior predictive accuracy compared to single-modality models in both internal and external validations. The deep learning-assisted EPE-grade scoring model significantly improved AUC and sensitivity compared to radiologist EPE-grade scoring alone (P < 0.05), with a modest reduction in specificity. Additionally, the deep learning-assisted scoring model provided greater clinical net benefit than the radiologist EPE-grade score used by radiologists alone.

conclusionThe multimodal imaging deep learning model, integrating mpMRI and 18 F-PSMA PET/CT, demonstrates promising predictive performance for EPE in prostate cancer and enhances the accuracy of radiologists in EPE assessment. The model holds potential as a supportive tool for more individualized and precise therapeutic decision-making.

Indexed as

Deep LearningMultimodal ImagingMultiparametric Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedExtranodal ExtensionFluorine RadioisotopesHumansMaleMiddle AgedProstatectomyRadiopharmaceuticalsRetrospective StudiesFluorine RadioisotopesRadiopharmaceuticalsDeep learningExtraprostatic extensionMagnetic resonance imagingMultimodal imagingPositron emission tomographyProstate cancer

Identifiers

PMID40830810
PMCPMC12366157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.